![nivolumab clone 5-h1 nivolumab clone 5-h1](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-47910-1/MediaObjects/41598_2019_47910_Fig1_HTML.png)
Received: ApAccepted: JPublished: August 12, 2015Ĭopyright: © 2015 Huang et al. PLoS ONE 10(8):Įditor: Ilya Ulasov, Swedish Neuroscience Institute, UNITED STATES (2015) The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells.
![nivolumab clone 5-h1 nivolumab clone 5-h1](https://www.science.org/cms/10.1126/scitranslmed.aav7431/asset/85e94c2b-fa8d-4a85-8a1e-b8e7e2ae2095/assets/graphic/aav7431-f1.jpeg)
Immunologic data of PCNA-positive cell ratios and CD45-positive cell ratios of the tumor specimens in the three groups were as follows: 1) control group: 65.72% (PCNA) and 0.92% (CD45), 2) NK treatment group: 27.66% (PCNA) and 13.46% (CD45), and 3) PD-1 inhibited NK cells treatment group: 13.66% (PCNA) and 23.66% (CD45) (P<0.001).Ĭitation: Huang BY, Zhan YP, Zong WJ, Yu CJ, Li JF, Qu YM, et al. The median survival of the mice in the three groups were as follows: 1) conrol group: 29 days, 2) NK cells treatment group: 35 days (P = 0.0012), 3) PD-1 inhibited NK cells treatment group: 44 days (P = 0.0024). In the in vivo experiments, the mice in the PD-1 inhibited NK cells treatment group and IL-2-stimulated-NK cells treatment group displayed a slowest tumor growth (F = 308.5, P<0.01) and a slower tumor growth compared with control group (F = 118.9, P<0.01), respectively. The mouse NK cells were identified as 90% CD3 - NK1.1 +CD335 + by flow cytometric analysis.